Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

NCT00602576 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

169

Enrollment

OTHER

Sponsor class

Conditions

Melanoma (Skin)

Interventions

DRUG: sorafenib tosylate
DRUG: temozolomide

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

[object Object]